Pancreatitis & Pancreatic Cancer News Articles

Development of Pancreatic Cancer Tx to Be Discontinued Following Disappointing Trial Results

November 5, 2019

Halozyme Therapeutics announced that the phase 3 HALO-301 study of PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreatic cancer has failed to meet the primary end point of overall survival.

SN-MMR was strongly associated with OS, melanoma-specific survival, and DFS among patients with a po

A Model for Predicting the Risk of Healthy Organ Exposure in Patients With Locally Advanced Pancreatic Cancer Treated With SBRT

October 22, 2019

Exceeding tolerances of healthy organs-at-risk as a result of daily anatomical deformations is a concern for patients with LAPC treated with SBRT.

A new study has suggested disrupted glucose metabolism is linked to high levels of DNA damage in the pancreas, which may contribute to the acquisition of KRAS mutations and subsequent carcinogenesis.

Resection Should Be Considered Even in Certain Smaller pNETs

October 18, 2019

Patients who had tumors measuring 1.5 cm to 2 cm were at double the risk for lymph node metastasis.

GEMOXEL regimen may be safe, more efficient than standard therapy for metastatic pancreatic cancer.

Virtual Molecular Tumor Board May Aid Treatment Selection

October 17, 2019

As cancer treatments become more complex, tumor boards can help simplify options.

Pancreatic Cancer: An Exocrine and Endocrine Disease

ASTRO Issues Guideline for Radiation Tx in Pancreatic Cancer

September 20, 2019

Evidence reviewed for radiation therapy in adjuvant, neoadjuvant, definitive, and palliative settings.

Dipeptidyl Peptidase-4 Inhibitors May Up Pancreatic Disease Risk

August 29, 2019

Risks for pancreatitis, pancreatic cancer higher in Korean patients with newly diagnosed T2DM.

New, less aggressive guidelines have been developed for management of pancreatic cysts.

Early Closure of Phase 2 Trial on Checkpoint Inhibitors in Metastatic PDAC Due to Missed Efficacy End Point

August 1, 2019

Pancreatic ductal adenocarcinoma is characterized by a tumor microenvironment that inhibits immune signaling.

Higher Fasting Plasma Glucose May Up Pancreatic Cancer Risk

July 30, 2019

Continuous increase in risk of pancreatic cancer with elevating fasting glucose, even within normal range.

Pain management continues to be a challenge for patients with pancreatic cancer, though CPN may prov

Novel Test Accurately Identifies Precancerous Pancreatic Cysts

July 19, 2019

Cyst classifier test is based on clinical and imaging features, genetic and biochemical markers.

Phase 3 Study Evaluating Novel Therapy for Pancreatic Cancer Discontinued

July 8, 2019

Boston Biomedical has announced that the CanStem111P study investigating napabucasin in patients with metastatic pancreatic cancer will be discontinued due to futility.

Some patients diagnosed with HP or AP have a significantly increased risk of developing pancreatic c

ASCO Guideline Update: Modified FOLFIRINOX Is Preferred as Adjuvant Chemotherapy in Patients With Resected Pancreatic Adenocarcinoma

June 18, 2019

The rate of grade 3/4 adverse events was higher for patients with resected pancreatic adenocarcinoma treated with adjuvant mFOLFIRINOX versus gemcitabine.

Maintenance Olaparib May Delay Progression of BRCA-Related Pancreatic Cancer

June 3, 2019

The median duration of response to olaparib in these patients with metastatic pancreatic cancer was more than 2 years.

Cancer Consultation Low in Noncurable Pancreatic Adenocarcinoma

May 30, 2019

Many patients with noncurable pancreatic adenocarcinoma do not have a specialized cancer consultation and most do not receive cancer-directed therapy.

Recent research shows that enoxaparin effectively prevents VTE complications in advanced pancreatic

FFPE Tissue Specimens Deemed Adequate for Molecular Studies: NCI-SEER

April 2, 2019

Regions of tumor and normal tissue on FFPE tissue specimens obtained from the NCI SEER-linked Virtual Tissue Repository were annotated by a pathologist.

Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial

March 4, 2019

Olaparib maintenance therapy improved PFS in patients with metastatic pancreatic adenocarcinoma characterized by a deleterious BRCA1/2 mutation.

Obesity enhances local myofibroblast content and stiffness-promoting extracellular matrix (ECM) comp

The Incidence of Some Obesity-Related Cancers Is Increasing Among Young Adults

February 5, 2019

Obesity in childhood and adolescence may be related to the disproportionate rise in certain obesity-related cancers in younger adults, according to authors.

FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer

January 3, 2019

Study results suggest a new combination regimen could become the standard of care for some patients.

As more treatment options became available in CML, along with increasing research into the disease s

Phase 1, 2 Trials to Assess Imaging System for Gastrointestinal Cancer Detection

December 18, 2018

Researchers are seeking to assess the initial safety and efficacy of LUM015 imaging of colorectal, pancreatic, and esophageal cancers using the LUM 2.6 imaging device.

Gastrinomas, rare endocrine tumors, can be treated in multiple ways, regardless of whether the tumor

Effect of Neuroendocrine Tumor Classification Updates on Survival Rates in Pancreatic Cancer

October 2, 2018

Survival rates for pancreatic cancer should be stratified by disease subgroup to better reflect prognostic differences across the subgroups in this category.

Local Delivery of Cytotoxic Microparticles in Pancreatic Cancer